Sign up to our newsletter
and receive exclusive information and discount coupons straight to your inbox


Top news by writer

Daniel Tomas
Tehnology Writer

HEALTH / The daily deal : a neck massager at an unbeatable price
As of this week, helpmeoutDOC has begun offering a series of massively discounted health items for sale. Today it is time to introduce our readers…
July 28, 2016 | 0 comments

Gabriel Rosoga
Medical and Health Writer

BEAUTY & SKIN CARE / Bee venom serums work miracles on skin
Bee venom, when used in small dosis, proves to be a very effective natural medicine, with extremely beneficial impact on the human organism, with particular…
September 8, 2016 | 1 comment

Ion Gireada
Science Writer

HEALTH / Reasons why your brain hears a ringing
Brain activity in people affected by tinnitus is very different from what happens when sound is detected in brains of healthy people, new research uncovered.…
April 27, 2015 | 0 comments

Ionut Popescu
Health and lifestyle writer

HEALTH / Brits oblivious to obesity leading to cancer
British population largely unware of link between obesity and cancer, finds new survey conducted by the organization Cancer Research UK. According to the survey, 75%…
September 9, 2016 | 0 comments

Cancer fighting approach disrupts cells from inside

by Ion Gireada on 6 March 2015
Health, Lifestyle, Medical technology     |      fighting cancer,  MYC,  Phylogica



colon_cancer
A new approach focusing on killing cancer “from the inside” promises a more effective way of defeating the disease, new research claims.

Researchers at Phylogica, located in Perth, Australian developed a new drug to fight cancer from the inside, by placing the active medication inside cells.

This approach takes a novel approach compared to traditional methods which reach only a tiny number of targeted cells.

Phylogica controls a library of billions of peptides, and uses the library to select those peptides that can be linked to drugs, serving as a key to unlock the cell’s outer protection to get inside.

“We’re about trying to take this new generation of smart drugs that they (big pharmaceutical firms) have been developing and deliver them much more efficiently inside the cells so they can access their targets,” Phylogica chief executive Richard Hopkins says.

With this technology, targets MYC, a protein that turns on genes that cause cancer and present in more than 50 per cent of all cancers.

“We have established potencies or activities against MYC that are unprecedented,” Dr Hopkins says.

“We are now embarking on a very aggressive transition from being perceived as a platform technology to applying that to very specific areas of need, specifically focused on cancer, around these high-value targets that no-one else has been able to touch before and which stretch across just about every type of cancer.”

Phylogica is seeking partners to help it expedite the path to a clinical trial.

Dr Hopkins says validating the company’s technology in animal trials will give Phylogica commercial traction.

“We’re sort of pulling together the pieces, and I think this is something we’ll articulate to the market over the coming weeks and months,” he says.

Phylogica is also taking to interested parties about “internationalizing” the company.

Last year Phylogica received an upfront payment of $500,000 and is eligible to receive discovery, development, and commercialization milestone payments totaling up to $142 million.



Cancer fighting approach disrupts cells from inside



colon_cancer
facebook pinterest google+